We are live on ! Find out more
FULC icon

Fulcrum Therapeutics

68 hedge funds and large institutions have $317M invested in Fulcrum Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 16

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

24% more capital invested

Capital invested by funds: $256M → $317M (+$60.8M)

3% more funds holding

Funds holding: 6668 (+2)

1.64% more ownership

Funds ownership: 80.74%82.38% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
68
Holders Change
+2
Holders Change %
+3.03%
% of All Funds
1.19%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
10
Increased
24
Reduced
16
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Russell Investments Group
76
Russell Investments Group
United Kingdom
-$15K -1,300 Closed

FULC Hedge Fund Activity: Q1 2021 in Review

68 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q1 2021, worth a combined $317M — up 24% from $256M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new FULC positions and 8 closed out — a net gain of 2 holders — while 24 added to existing stakes and 16 trimmed.

The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $18.9M. The largest seller was Point72 Asset Management, cutting an estimated $9.43M.

  • 68 institutional investors held Fulcrum Therapeutics (FULC) as of Q1 2021, up from 66 in Q4 2020.
  • Funds reported $317M of Fulcrum Therapeutics stock for Q1 2021, up 24% quarter-over-quarter.
  • 10 funds opened new Fulcrum Therapeutics positions in Q1 2021 and 8 closed out, a net change of +2 holders.
  • The largest Fulcrum Therapeutics buyer in Q1 2021 was Suvretta Capital Management, an estimated $18.9M added.
  • The largest Fulcrum Therapeutics seller in Q1 2021 was Point72 Asset Management, an estimated $9.43M sold.

Based on aggregated 13F filings for Q1 2021.